SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, IMPROVES QUALITY OF LIFE IN PATIENTS WITH COLD AGGLUTININ DISEASE: PATIENT-REPORTED OUTCOMES RESULTS OF THE PHASE 3 CARDINAL STUDY

被引：0
|
作者：
Barcellini, W. [1 ]
Roth, A. [2 ]
Tvedt, T. H. Anderson [3 ]
Miyakawa, Y. [4 ]
Kuter, D. J. [5 ]
Hobbs, W. [6 ]
Su, J. [6 ]
Jiang, X. [6 ]
Morales Arias, J. [6 ]
Weitz, I. C. [7 ]
机构：
[1] Fdn IRCCS Ca Granda Ospedale Maggiore Policlin, Milan, Italy
[2] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Hematol, Essen, Germany
[3] Haukeland Hosp, Dept Med, Sect Hematol, Bergen, Norway
[4] Saitama Med Univ Hosp, Thrombosis & Hemostasis Ctr, Saitama, Japan
[5] Harvard Med Sch, Massachusetts Gen Hosp, Div Hematol, Boston, MA 02115 USA
[6] Sanofi, Cambridge, MA USA
[7] Univ Southern Calif, Keck Sch Med, Dept Med, Jane Anne Nohl Div Hematol, Los Angeles, CA 90007 USA
来源：
HAEMATOLOGICA | 2021年 / 106卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
D012
引用
收藏
页码：111 / 112
页数：2
相关论文
共 50 条
  • [1] Sutimlimab, a complement C1s inhibitor, improves quality of life in patients with cold agglutinin disease: Patient-reported outcomes results of the phase 3 cardinal study
    Roeth, A.
    Barcellini, W.
    Tvedt, Anderson T. H.
    Miyakawa, Y.
    Kuter, D. J.
    Hobbs, W.
    Su, J.
    Jiang, X.
    Arias, Morales J.
    Weitz, I. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 179 - 180
  • [2] Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study
    Alexander Röth
    Wilma Barcellini
    Tor Henrik Anderson Tvedt
    Yoshitaka Miyakawa
    David J. Kuter
    Jun Su
    Xiaoyu Jiang
    William Hobbs
    Jaime Morales Arias
    Frank Shafer
    Ilene C. Weitz
    Annals of Hematology, 2022, 101 : 2169 - 2177
  • [3] Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study
    Roeth, Alexander
    Barcellini, Wilma
    Tvedt, Tor Henrik Anderson
    Miyakawa, Yoshitaka
    Kuter, David J.
    Su, Jun
    Jiang, Xiaoyu
    Hobbs, William
    Arias, Jaime Morales
    Shafer, Frank
    Weitz, Ilene C.
    ANNALS OF HEMATOLOGY, 2022, 101 (10) : 2169 - 2177
  • [4] INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FROM THE PHASE 3 CARDINAL STUDY
    Roeth, A.
    Barcellini, W.
    D'Sa, S.
    Miyakawa, Y.
    Broome, C. M.
    Michel, M.
    Kuter, D. J.
    Jilma, B.
    Tvedt, T. H. Anderson
    Lin, S.
    Jiang, X.
    Reuter, C.
    Hobbs, W.
    Berentsen, S.
    HAEMATOLOGICA, 2020, 105 : S38 - S38
  • [5] Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study
    Roth, Alexander
    Barcellini, Wilma
    D'Sa, Shirley
    Miyakawa, Yoshitaka
    Broome, Catherine M.
    Michel, Marc
    Kuter, David J.
    Jilma, Bernd
    Tvedt, Tor Henrik Anderson
    Lin, Stella
    Jiang, Xiaoyu
    Reuter, Caroline
    Hobbs, William
    Berentsen, Sigbjorn
    BLOOD, 2019, 134
  • [6] Results from the phase 3 Cardinal study part A: Inhibition of complement C1s with Sutimlimab in patients with Cold Agglutinin Disease (CAD)
    Roeth, A.
    Barcellini, W.
    Sa, D. S.
    Miyakawa, Y.
    Broome, C. M.
    Michel, M.
    Kuter, D. J.
    Jilma, B.
    Tvedt, Anderson T. H.
    Lin, S.
    Jiang, X.
    Reuter, C.
    Hobbs, W.
    Berentsen, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 177 - 177
  • [7] INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): INTERIM RESULTS OF THE PHASE 3 CARDINAL STUDY LONG -TERM FOLLOW-UP
    Barcellinia, W.
    Roeth, A.
    D'Sa, S.
    Miyakawa, Y.
    Broome, C. M.
    Michel, M.
    Kuter, D. J.
    Jilma, B.
    Tvedt, T. H. Anderson
    Weitz, I. C.
    Patel, P.
    Jiang, X.
    Reuter, C.
    Su, J.
    Shafer, F.
    Lee, M.
    Hobbsb, W.
    Berentsen, S.
    HAEMATOLOGICA, 2021, 106 (10) : 107 - 107
  • [8] Interim results of the phase 3 CARDINAL study long-term follow-up: Inhibition of complement C1s with sutimlimab in patients with Cold Agglutinin Disease (CAD)
    Roeth, A.
    Barcellini, W.
    D'Sa, S.
    Miyakawa, Y.
    Broome, C.
    Michel, M.
    Kuter, D.
    Jilma, B.
    Tvedt, T. H. A.
    Weitz, I. C.
    Patel, P.
    Jiang, X.
    Reuter, C.
    Su, J.
    Shafer, F.
    Lee, M.
    Hobbs, W.
    Berentsen, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 169 - 170
  • [9] Sutimlimab: A Complement C1s Inhibitor for the Management of Cold Agglutinin Disease-Associated Hemolysis
    Moore, Donald C.
    Arnall, Justin R.
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (08) : 970 - 977
  • [10] Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Interim Results of the Phase 3 Cardinal Study Long-Term Follow-up
    Roth, Alexander
    Barcellini, Wilma
    D'Sa, Shirley
    Miyakawa, Yoshitaka
    Broome, Catherine M.
    Michel, Marc
    Kuter, David J.
    Jilma, Bernd
    Tvedt, Tor Henrik Anderson
    Weitz, Ilene C.
    Patel, Parija
    Jiang, Xiaoyu
    Reuter, Caroline
    Su, Jun
    Shafer, Frank
    Lee, Michelle
    Hobbs, William
    Berentsen, Sigbjorn
    BLOOD, 2020, 136
12345